Abstract
The Efficacy and Safety of Caplacizumab in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): An Open-Label, Phase 2/3 Study
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have